24 25 Key words: Pseudomonas aeruginosa; persisters; stationary phase bacteria; ranking of antibiotics; 26 clinafloxacin, cystic fibrosis 27 28 29 30 31 32 33 34 Abstract 35 Pseudomonas aeruginosa can cause serious persistent infections such as ventilator-associated 36 pneumonia, sepsis, biofilm-related infections as in cystic fibrosis (CF) patients. Although CF lung 37 infections can be treated with antibiotics, full clearance is difficult due to P. aeruginosa persistence. 38 While antibiotic activity against growing P. aeruginosa is well documented, their activity against 39 the non-growing persisters enriched in stationary phase cultures has not been well studied. Here, 40 we systematically evaluated and ranked the six major classes of antibiotics, cell wall and cell 41 membrane inhibitors, protein synthesis inhibitors, DNA synthesis inhibitors, RNA synthesis 42 inhibitors, sulfa drugs, and nitrofurantoin, for their activity against both growing and persister 43 forms of P. aeruginosa using colony forming count (CFU) and SYBR Green I/Propidium Iodide 44 (PI) viability assay. Among the six major classes of antibiotics, cell wall and cell membrane 45 inhibitors (Cefuroxime and Colistin), DNA synthesis inhibitors (Clinafloxacin) and sulfa drugs 46 (Sulfamethoxazole) had good activity against stationary phase cells. In contrast, protein synthesis 47 inhibitors (Gentamicin), RNA synthesis inhibitor (Rifampicin) and Nitrofurantoin had relatively 48 poor activity against the stationary phase P. aeruginosa but relatively high activity against log 49 phase P. aeruginosa. Clinafloxacin is the only single drug that could completely kill all (10 9 CFU) 50 stationary phase cells in a 4 day drug exposure. The Cefuroxime + Gentamicin+ Clinafloxacin 51 combination could kill all biofilm bacteria in 2 days whereas the clinically used drug combination 52 Cefuroxime + Gentamicin + Colistin only partially killed the biofilm bacteria with 10 3 CFU 53 remaining. In a murine persistent CF lung infection model, only Cefuroxime + Gentamicin+ 54 Clinafloxacin cleared all bacteria in the infected lungs, whereas Clinafloxacin alone, or Cefuroxime 55 + Clinafloxacin, or the current recommended drug combination Cefuroxime + Gentamicin, all 56 failed to completely clear the bacterial load in the lungs. The complete sterilization of the bacterial 57 load is a property of Clinafloxacin combination, as Cefuroxime + Gentamicin+ Levofloxacin 58 combination was unable to clear the bacterial load in the lungs. Our findings demonstrate the 59 importance of persister drug clinafloxacin, offer new therapeutic approaches for more effective 60 treatment of persistent P. aeruginosa infections, and may have implications for treating other 61 persistent infections. 62 63 64 65 Introduction 66
Viable bacterial cells were determined by CFU count after drug exposure at days 2, 4, 6 and 10 as 137 described (Harley 2008) . First, bacterial suspensions (50 μ L) after drug exposure were washed with 138 fresh TSB medium twice and serial dilutions were prepared. 10 μ L of each dilution was dropped 139 onto TSA plates in triplicate followed by incubation at 37 ℃ overnight. The CFU/ml was 140 calculated accordingly. 141 142 SYBR Green I/PI assay for P. aeruginosa 143
The staining dyes were prepared by mixing SYBR Green I/PI (10,000X stock, Invitrogen) with 144 propidium iodide (20 mM, Sigma-Aldrich) in distilled water and the ratio of SYBR Green I to 145 propidium iodide was 1:3 in 100 µl distilled H 2 O(Feng et al. 2014). The drug treated samples were 146 aliquoted and diluted 1:50 with fresh TSB medium. The SYBR Green I/PI dye mix (10 µL) was 147 added to each 100 µL of sample. Each sample was vortexed and incubated at room temperature in 148 the dark for 20 minutes. After incubation, each sample was transferred into 96-well plate. With 149 excitation wavelength of 485 nm and 538 nm and 612 nm for green and red emission, respectively, 150 the green and red fluorescence intensity was determined for each sample using a Synergy H1 151 microplate reader by BioTek Instruments (VT, USA). To generate the regression equation and ratios, different proportions of live and 70% isopropyl alcohol killed dead cells were prepared (0:10, 154 1:4, 5:5, 4:1, 10:0) and both live and dead samples were diluted 50 times with fresh TSB medium 155 first. Each proportion of live/dead P. aeruginosa was mixed with SYBR Green I/PI dye into each 156 well of 96-well plate and the green/red fluorescence ratios were measured as described above, 157 generating standard curve and equation with least-square fitting analysis. We used this equation to 158 calculate the percentage of live cells of P. aeruginosa. Fluorescence microscopy imaging visualizing 159 live and dead cells was performed using a Keyence BZ-X710 Fluorescence Microscope and was 160 processed by BZ-X Analyzer provided by Keyence (Osaka, Japan). 161
162
The MIC (minimum inhibitory concentration) determination 163
The standard microdilution method was used to determine the MIC of each antibiotic as described 164 
Ranking of major classes of antibiotics for activity against stationary phase P. aeruginosa 242
To determine the relative activity of different classes of antibiotics against stationary phase P. 243 aeruginosa, we performed drug exposure assays (all at 25 μ M) with cell wall inhibitor (e.g. 244 Cefuroxime), cell membrane inhibitor (Colistin), DNA synthesis inhibitor (e.g. Clinafloxacin) , 245 protein synthesis inhibitor (e.g. Gentamicin), RNA synthesis inhibitor (e.g. Rifampicin), Sulfa drug 246 (e.g. Sulfamethoxazole), and Nitrofurantoin against P. aeruginosa stationary phase bacteria ( Figure  247 2A). After 2 days of drug exposure, Clinafloxacin showed the highest activity in killing stationary 248 phase bacteria, resulting in 0 CFU ( Figure 2B ). Cefuroxime and Colistin, cell wall and cell 249 membrane inhibitors, respectively, and Sulfamethoxazole, had high activity against stationary 250 phase bacteria compared with the drug free control. In contrast, Gentamicin, Rifampicin and 251
Nitrofurantoin showed poor activity against the stationary phase P. aeruginosa. 252
253
Although the standard CFU assay can be used to evaluate the activity of antibiotics against 254 stationary phase P. aeruginosa, we wanted to rank the same antibiotics by using the SYBR Green 255 I/PI assay which is a more rapid method (Feng et al. 2014). Our results generated by SYBR Green 256 I/PI viability assay correlated with findings from the CFU counting assay ( Figure 3A ). Cefuroxime 257 and Colistin, Sulfamethoxazole and Clinafloxacin had among the highest activity against the 258 stationary phase P. aeruginosa. The other three classes of antibiotics as represented by Gentamicin, 259
Rifampicin and Nitrofurantoin had poor activity. We then calculated the residual viable bacterial 260 cells after 10 day drug exposure through the regression equation (Table 1 ). After 10 days of 261 treatment, Colistin killed the highest number of stationary phase bacteria, and Cefuroxime, 262
Sulfamethoxazole and Clinafloxacin also showed remarkable effects with low percentages of 263 residual viable bacterial cells remaining ( Figure 3B Cell wall inhibitors usually do not have good activity against persisters. Here, we found that 283 cefuroxime at 25 μ M reduced stationary phase bacteria from 10 9 to 10 6 CFU/ml ( Figure 2B ). To 284 determine if it is the specific activity of cephalosporin cefuroxime against persisters, we tested 285 other cell wall inhibitors such as amoxicillin and meropenem and found that compared to the 286 dramatic persister killing activity of cefuroxime, amoxicillin and meropenem had limited activity 287 against P. aeruginosa persisters as more than 10 7 CFU/ml bacteria remaining after 7-day drug 288 exposure ( Figure 5A . Thus, we also tried 305 to make a ranking among the six major classes of antibiotics (cell wall inhibitor, cell membrane 306 disruptor, protein synthesis inhibitor, DNA synthesis inhibitor, RNA synthesis inhibitor, and 307 anti-metabolite folate inhibitor) for their ability to kill growing log-phase bacteria. Based on the 308 MIC values determined, our data showed that Colistin and Clinafloxacin had the lowest MIC 309 values for P. aeruginosa PAO-1 strain (Table 2) , which demonstrated that these two antibiotics can 310 effectively kill both log phase and stationary phase bacteria. We also observed that Gentamicin was 311 highly active against log phase bacteria but had low activity against stationary phase bacteria. 312
Conversely, Cefuroxime and Sulfamethoxazole were less effective against growing PAO-1 bacteria, 313 both with MICs above 16 μ g/mL, but were effective in killing stationary phase bacteria (Tables 1 &  314 2). Rifampicin and Nitrofurantoin had low activity against both growing and stationary phase P. Clinically, it has been challenging to cure persistent infections like P. aeruginosa lung infections in 367 cystic fibrosis patients. The difficulty to cure the persistent infections is thought to be mainly due 368 to persister bacteria that are not effectively killed by the current antibiotics used to treat such 369 infections. To address this hypothesis, here, we first ranked the six major classes of antibiotics for 370 their activity against P. aeruginosa persisters in vitro and found a ranking order based on both CFU 371 count and our SYBR Green/PI results: clinafloxacin > colistin > gentamicin > cefuroxime > 372 sulfamethoxazole > rifampicin > nitrofurantoin ( Figure 2B; Figure 3 ; Table 1 ). Among different 373 cell wall inhibitors, cefuroxime showed greater activity to kill P. aeruginosa persisters than 374 amoxicillin and meropenem ( Figure 5A ). Among different quinolone antibiotics, clinafloxacin 375 killed all persister bacteria after 2 day drug exposure but other quinolones were not able to 376 eradicate all persisters even after 7-day drug exposure ( Figure 5B ), suggesting that clinafloxacin 377 could be a potential persister drug candidate for inclusion in drug combinations to kill persisters 378 and biofilm bacteria. Based on the Yin-Yang model (Zhang 2014) utilizing drugs with activity 379 against growing bacteria (MICs) and anti-persister activity results (Table 2) Cef + Gen completely eradicated biofilm bacteria in vitro ( Figure 6) , and more importantly, the 407 persistent lung infection in mice (Figure 7) . 408 409 Our effective drug combination findings successfully apply the 'Yin-Yang' model to kill both 410 replicating log phase bacteria (Yang) and also non-replicating persister bacteria(Yin) (Zhang 2014) . 411
In the Tuberculosis (TB) therapy, isoniazid (INH) is only active for growing mycobacteria, 412 rifampin (RIF) is used to kill both growing and non-growing bacteria, and pyrazinamide (PZA) is 413 added to kill exclusively non-growing persister bacteria in the treatment of TB (Zhang, Yew, and 414 Barer 2012). The importance of PZA in killing persister TB bacteria and shortening the TB therpay 415 without relapse is mainly recognized in the TB field (Zhang, Yew, and Barer 2012) and not 416 appreciated in other persistent infections. We proposed to apply the PZA persister drug principle 417 for the treatment of other infections (Zhang et al. 2013 ). This PZA principle has been shown to be 418 valid in subsequent studies with different bacteria such as B. burgdorferi (Feng, Auwaerter, and if the unique anti-persister activity is due to the chloride group and to further optimize the activity 435 of clinafloxacin for anti-persister activity and to reduce its potential toxicity. Second, the 436 mechanism of the unique anti-persister activity in clinfloxacin is not known but could be due to its 437 activity on the bacterial cell membrane, as it is known that several persister drugs such as 438 pyrazinamide (Zhang and Mitchison 2003) of its adverse drug reactions such as photosensitivity and hypoglycemia (Siami, LaFleur, and Siami 445 2002) . It remains to be determined if the unique high anti-persister activity of clinafloxacin could 446 outweigh its potential side effect in case of difficult to treat persistent infections. Thus, although 447 our findings are encouraging, further studies are needed to address the above issues and its unique 448 mechanism of anti-persister activity and its potential safety concerns in the future. ; Clin
